(Q50911460)

25 March 2018

title

Long-term emotional state of multiple sclerosis patients treated with interferon beta. (English)

1 reference

25 March 2018

0 references

5

1 reference

25 March 2018

author name string

J Porcel

1

1 reference

25 March 2018

J Río

2

1 reference

25 March 2018

A Sánchez-Betancourt

3

1 reference

25 March 2018

M J Arévalo

4

1 reference

25 March 2018

N Téllez

6

1 reference

25 March 2018

C Borràs

7

1 reference

25 March 2018

C Nos

8

1 reference

25 March 2018

X Montalbán

9

1 reference

25 March 2018

publication date

1 December 2006

1 reference

25 March 2018

Multiple Sclerosis Journal

published in

1 reference

25 March 2018

volume

12

1 reference

25 March 2018

issue

6

1 reference

25 March 2018

page(s)

802-807

1 reference

25 March 2018

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070748

Multiple sclerosis: side effects of interferon beta therapy and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070748

Depression in multiple sclerosis associated with interferon beta-1a (Rebif).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070748

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070748

Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070748

Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070748

Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070748

Depressive symptoms in a treated multiple sclerosis cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070748

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070748

The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070748

Development of a Rating Scale for Primary Depressive Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070748

An Inventory for Measuring Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070748

The relationship between disability and depression in multiple sclerosis: the role of uncertainty, coping, and hope

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070748

21 January 2018

Identifiers

DOI

10.1177/1352458506070748

1 reference

25 March 2018

1 reference

25 March 2018